Last update 01 Nov 2024

Alcohol Withdrawal Seizures

Last update 01 Nov 2024

Basic Info

Synonyms

ALCOHOL WITHDRAWAL SEIZURE, Alcohol Related Seizures, Alcohol Withdrawal Induced Major Motor Seizure

+ [62]

Introduction

A condition where seizures occur in association with ethanol abuse (ALCOHOLISM) without other identifiable causes. Seizures usually occur within the first 6-48 hours after the cessation of alcohol intake, but may occur during periods of alcohol intoxication. Single generalized tonic-clonic motor seizures are the most common subtype, however, STATUS EPILEPTICUS may occur. (Adams et al., Principles of Neurology, 6th ed, p1174)

Drugs associated with Alcohol Withdrawal Seizures

Levetiracetam

Target

SV2A

Mechanism

SV2A modulators

Active Org.

Ratiopharm GmbH [+21]

Originator Org.

UCB SA

Active Indication

Epilepsia Partialis Continua [+10]

Inactive Indication

Acute repetitive seizure [+28]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date30 Nov 1999

Clinical Trials associated with Alcohol Withdrawal Seizures

NCT06006442 / WithdrawnNot ApplicableIIT

Vaping-Related Seizures - A Prospective Case-Crossover Study

This case-crossover study evaluates the association between vaping and seizures in patients of a large academic medical center who admits to vaping and hav a planned ambulatory EEG ordered.

Start Date01 Sep 2023

Sponsor / Collaborator

Dartmouth-Hitchcock Medical Center

IRCT20230323057767N1 / CompletedNot ApplicableIIT

Comparing the Effectiveness of Cognitive Group Therapy and Spiritual Therapy on Reducing Cravings, Relapse Prevention, Life Quality Improvement, Overall Function and Lifestyle of Addicts.

Start Date05 May 2023

Sponsor / Collaborator

Islamic Azad University

EUCTR2021-002188-23-DK / Not yet recruitingPhase 4IIT

Association between variations in CYP pheno- and genotypes and plasma concentration of chlordiazepoxide in the treatment of alcohol withdrawal symptoms

Start Date01 Dec 2021

Sponsor / Collaborator

Bispebjerg Hospital

100 Clinical Results associated with Alcohol Withdrawal Seizures

100 Translational Medicine associated with Alcohol Withdrawal Seizures

0 Patents (Medical) associated with Alcohol Withdrawal Seizures

423

Literatures (Medical) associated with Alcohol Withdrawal Seizures

01 Sep 2024·BMJ Case Reports

Topiramate-induced acute eosinophilic pneumonia

Article

Author: Tyagi, Rahul ; Suyal, Utkarsh ; Aggarwal, Monika ; Pandey, Indramani

A man in his 40s with a known history of alcohol dependence syndrome was admitted with presenting symptoms of alcohol withdrawal. During his admission, he developed breathlessness, cough and wheezing. Investigations revealed raised absolute eosinophil count and serum IgE levels. Chest imaging showed ill-defined opacities and fibreoptic bronchoscopy with bronchoalveolar lavage confirmed eosinophilic pneumonia. Extensive workup for the cause of eosinophilia was negative. The patient’s medicines were reviewed, and it was realised that the onset of eosinophilia occurred after starting topiramate for an alcohol withdrawal seizure. The drug was stopped, leading to the complete resolution of symptoms and radiological abnormalities. This case highlights the importance of considering drug-induced causes of eosinophilic pneumonia.

01 Aug 2024·Epilepsy Currents

Over the Limit; Long-Term Seizure and Mortality Risk in Alcohol Withdrawal Seizures

Article

Author: Widdess-Walsh, Peter

[Box: see text]

02 Jul 2024·Clinical Toxicology

Oral ethanol prescribing for alcohol withdrawal syndrome: initial findings and future directions following implementation within a United Kingdom National Health Service setting

Article

Author: John, Bev ; Appleyard, Carol ; Kaur, Jatinder ; Roderique-Davies, Gareth ; Quelch, Darren ; Bradberry, Sally ; Copland, Arlene ; Williams, Grace ; Davies, Nyle ; Nevill, Alan ; Knight, Thomas ; Sarma, Nikhil

INTRODUCTIONPrescribing of ethanol may be an alternative to benzodiazepines for managing alcohol withdrawal syndrome. We present our experience of oral ethanol prescribing within an acute United Kingdom National Health Service setting.METHODSA retrospective review of patients presenting with alcohol withdrawal who were managed with oral ethanol or benzodiazepines was performed from data collected across two acute care settings. Ethanol prescribing inclusion: high risk of delirium tremens, or a history of harmful alcohol consumption (typically ≥30 units/day; in which 1 unit = 8 grams of alcohol; one standard United States drink = 14 grams of alcohol) or known to have a history of severe alcohol withdrawal, alcohol-related seizures or delirium tremens. Inverse propensity score weighting was used to partially account for variance between the two patient populations.RESULTSFifty (82 per cent male; average age 50.9 years) and 93 (84 per cent male; average age 46.5 years) patients in receipt of benzodiazepines or ethanol, respectively, were included. The likelihood of hospital admission was significantly reduced when individuals were managed with ethanol (odds ratio 0.206 (95 per cent confidence interval; 0.066-0.641), Wald chi-square P = 0.006). In those not admitted, the treatment type had no significant impact on length of stay or the number of occasions a pharmacological agent was required. In those admitted, treatment had no significant effect on length of stay.DISCUSSIONWe offer preliminary evidence to support a role of oral ethanol in the management of patients with alcohol withdrawal. We have implemented a robust and translatable guideline. Despite limitations in the data set the impact of ethanol in reducing the likelihood of admission remained significant.CONCLUSIONSIn individuals at significant risk of severe alcohol withdrawal, prescribing ethanol as part of a comprehensive care plan, may reduce unplanned admissions. The preliminary findings presented here warrant further assessment through prospective studies.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis